IBRX
NASDAQ · Biotechnology
Immunitybio Inc
$7.64
+0.32 (+4.37%)
Financial Highlights (FY 2026)
Revenue
127.84M
Net Income
-396,378,785
Gross Margin
99.3%
Profit Margin
-310.2%
Rev Growth
+678.6%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.3% | 46.7% | 46.7% | 46.7% |
| Operating Margin | -226.0% | 13.5% | 15.6% | 16.2% |
| Profit Margin | -310.2% | 11.2% | 12.9% | 10.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 127.84M | 1.55B | 1.61B | 1.37B |
| Gross Profit | 126.99M | 724.51M | 749.85M | 638.37M |
| Operating Income | -288,912,401 | 209.37M | 250.31M | 221.59M |
| Net Income | -396,378,785 | 174.18M | 206.87M | 144.80M |
| Gross Margin | 99.3% | 46.7% | 46.7% | 46.7% |
| Operating Margin | -226.0% | 13.5% | 15.6% | 16.2% |
| Profit Margin | -310.2% | 11.2% | 12.9% | 10.6% |
| Rev Growth | +678.6% | +14.4% | +15.1% | +21.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 25.99M | 1.85B | 1.81B | 2.26B |
| Total Equity | 3.94B | 2.71B | 2.28B | 2.30B |
| D/E Ratio | 0.01 | 0.68 | 0.80 | 0.98 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -271,343,068 | 310.76M | 319.11M | 261.81M |
| Free Cash Flow | — | 125.72M | 219.44M | 149.39M |